The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 15 rounds in the feed, most often at Series A and in Biotech.
Venture capitalbayernkapital.deRounds from 2020-07-21 to 2026-10-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Elevatry An AI platform for strategic procurement | Pre-seed Verified against 4 of 12 sources | $3.4M | 2026-10-15 | [ PART ] |
Finches A platform designed to help companies that depend on agricultural raw materials identify potential supply risks earlier | Pre-seed |
| $2.2M |
| 2026-10-06 |
| [ PART ] |
Arcos Arcos sells cybersecurity solutions focused on protecting critical infrastructure, targeting sectors like public, commercial, and residential. | Seed Verified against 1 of 11 sources | $6.3M | 2026-09-18 | [ PART ] |
HyImpulse A German launch services provider | Series A ext. Verified against 4 of 5 sources | $58.1M | 2026-09-02 | [ PART ] |
Proxima Fusion A startup commercializing stellarator fusion | Series A Verified against 1 of 20 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $469.9M | 2026-07-07 | [ PART ] |
constellr A space-tech startup specializing in thermal infrared Earth observation | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $44.0M | 2026-02-10 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ PART ] |
IQM Quantum Computers IQM builds full-stack superconducting quantum computers, primarily for high-performance computing, researchers, and enterprises. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $320M | 2025-09-03 | [ PART ] |
Proxima Fusion A startup commercializing stellarator fusion | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $148.6M | 2025-06-11 | [ PART ] |
Isar Aerospace Isar Aerospace provides launch services for small and medium-sized satellites, enabling access to space through their innovative launch vehicle, Spectrum. | Series C ext. Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $69.7M | 2024-06-20 | [ PART ] |
Proxima Fusion A startup commercializing stellarator fusion | Seed Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $21.7M | 2024-04-10 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $139.8M | 2024-03-14 | [ PART ] |
IQM Quantum Computers IQM builds full-stack superconducting quantum computers, primarily for high-performance computing, researchers, and enterprises. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130.4M | 2022-07-22 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63.3M | 2022-05-03 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.2M | 2020-07-21 | [ PART ] |